Latest news with #DavidHorn
.jpg%3Fwidth%3D1200%26auto%3Dwebp%26quality%3D75%26crop%3D3%3A2%2Csmart%26trim%3D&w=3840&q=100)
Scotsman
06-05-2025
- Sport
- Scotsman
12 ex-Rangers players available as free agents this summer - including five Ibrox title winners and 5-cap ace
As Rangers approach their final three fixtures of the Scottish Premiership season, the transfer rumour mill is beginning to turn its wheels and readying itself for the Ibrox giants to be linked with a number of names in the summer. With an imminent takeover on the way from an American consortium involving the San Francisco 49ers and a permanent manager to be appointed, it will almost certainly be another hectic summer in Govan as Rangers look to close the widening gap on their near neighbours Celtic, with incomings and exits expected. They won't be the only club included in the transfer merry-go-round though, with a number of teams writing up their transfer wishlists ahead of the window reopening next month. A number of big names and upcoming talents have come and gone from Rangers over the years and there remains some who have will have uncertain futures outside of Ibrox in just a few weeks. Here are 12 former Rangers players who have contracts expiring this summer as things stand. 1 . Daniel Candeias - Adanaspor Signed the previous year by ex-boss Pedro Caixinha, the Portuguese midfielder was a regular starter for Gerrard in his first two years at Ibrox before he was allowed to depart in order to sign for for Gençlerbirliği in 2019 to end his spell in Scotland. Now 37, Candeias plays for Turkish second tier side Adanaspor but will see his contract expire in a few weeks. | SNS Group Photo: SNS Group Photo Sales 2 . Kal Naismith - Bristol City Currently on the books of Bristol City, Naismith build up a strong reputation as a physical, athletic midfielder in the EFL Championship in recent years, but has been curtailed by form and injury of late. Spent the season on loan to relegated Luton Town, but played just 10 times as the Hatters suffered back-to-back relegations. | David Horn Photo: David Horn Photo Sales 3 . Glenn Middleton - Dundee United Recently hit a century of appearances at Tannadice, where he has played regularly since signing for Dundee United back in 2022. Has made no secret of his contentment at the club, but is yet to put pen to paper on a new deal with Jim Goodwin's team. | SNS Group Photo: SNS Group Photo Sales 4 . Barrie McKay - Hearts Once an Old Firm hero for Rangers in a Scottish Cup semi-final at Hampden, injury has largely hampered his time at Tynecastle after a very bright start to life in the capital. Has featured in just eight league games for the Jambos this year, and looks set to become a free agent at the end of this month. | SNS Group Photo: SNS Group Photo Sales
Yahoo
28-02-2025
- Business
- Yahoo
Seer Inc (SEER) Q4 2024 Earnings Call Highlights: Navigating Revenue Decline with Strategic ...
Fourth Quarter Revenue: $4 million, a decrease of 10% from $4.4 million in Q4 2023. Full Year Revenue: $14.2 million, a decrease of 15% from $16.7 million in 2023. Gross Margin (Q4 2024): 51%, up from 45% in Q4 2023. Net Loss (Q4 2024): $21.7 million, compared to $17.8 million in Q4 2023. Net Loss (Full Year 2024): $86.6 million, compared to $86.3 million in 2023. Cash, Cash Equivalents, and Investments: Approximately $300 million as of December 31, 2024. Share Repurchase: Approximately 6.5 million shares repurchased, reducing shares outstanding by 10% to 59 million. Free Cash Flow Loss (Full Year 2024): $49.4 million, down from $66.4 million in 2023. 2025 Revenue Guidance: Expected to be in the range of $17 million to $18 million. Warning! GuruFocus has detected 3 Warning Sign with SEER. Release Date: February 27, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Seer Inc (NASDAQ:SEER) reported a total revenue of $14.2 million for 2024, with a strong cash position of approximately $300 million. The company successfully repurchased approximately 6.5 million shares, reducing the total shares outstanding by about 10%. Seer Inc (NASDAQ:SEER) expanded its global reach, serving over 135 customers across 20 countries, and doubled its commercial team in North America. The Proteograph Product Suite has been validated through 33 customer publications, with 23 new peer-reviewed publications in 2024. Seer Inc (NASDAQ:SEER) has formed a strategic partnership with Thermo Fisher Scientific to co-market and sell the Proteograph Product Suite, enhancing commercial reach. Total revenue for 2024 decreased by 15% compared to 2023, primarily due to lower product sales and no grant revenue. The company reported a net loss of $86.6 million for the full year 2024, slightly higher than the $86.3 million loss in 2023. Seer Inc (NASDAQ:SEER) experienced a 10% decrease in fourth-quarter revenue compared to the same period in 2023, due to lower instrument sales. There is ongoing uncertainty regarding NIH and government funding, which could impact a portion of Seer Inc (NASDAQ:SEER)'s revenue in 2025. The company faces challenges with elongated sales cycles and pressure on CapEx budgets, affecting the outright purchase of new instruments. Q: How should we think about the split between instruments and consumables in 2025, and what is the expected pacing for the first and second half of the year? A: Omid Farokhzad, CEO, noted that 2024 was challenging for CapEx, with instrument placements skewed towards the latter half of the year. For 2025, they anticipate a different pace, with a stronger start due to a robust pipeline. David Horn, CFO, added that the product revenue breakdown will likely mirror 2024, with product revenue comprising about 72% and service revenue 27%. They expect more instrument placements and increased interest in larger projects. Q: Can you discuss the trajectory of the STAC program and its revenue outlook for 2025? A: Omid Farokhzad explained that the STAC program is not intended to expand into a service company, so capacity will remain consistent. Revenue growth is expected as early collaborations were priced lower, but now projects are priced closer to standard service rates. David Horn added that demand from large pharma and academic customers is strong, with repeat customers and increased ASPs contributing to positive trends. Q: What impact do NIH funding uncertainties have on your business, and what trends are you seeing with academic customers? A: Omid Farokhzad stated that about 30% of their revenue comes from government and academic entities. While indirect funding cuts could affect broader organizational investments, direct research funding remains intact. They have factored in a cautious outlook for these accounts in their guidance. David Horn noted that uncertainty is causing some delays, but some customers have confirmed their funding and are proceeding. Q: What does the publication pipeline look like for 2025, and are there any significant projects on the horizon? A: Omid Farokhzad highlighted that customer publications have been a bright spot, with over 30 publications to date. The STAC program facilitates quick data access, aiding in grant writing and presentations. He expects the pace of publications to continue in 2025, with recent conferences showcasing significant research enabled by their technology. Q: What is the expected impact of the Thermo Fisher collaboration on 2025 guidance, and are there plans for similar partnerships? A: David Horn mentioned that the Thermo Fisher collaboration is being operationalized in Q2 2025, with modest expectations built into the guidance. Omid Farokhzad added that while the Thermo partnership is non-exclusive, they are open to other collaborations to enhance access to their Proteograph technology, with ongoing discussions with other mass spec providers. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
